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Abstract
While chronic hypoglycaemia has been reported to increase
unidirectional glucose transport across the blood–brain barrier
(BBB) and to increase GLUT1 expression at the endothelium,
the effect on steady-state brain D-glucose and brain glycogen
content is currently unknown. Brain glucose and glycogen
concentrations were directly measured in vivo using localized
13C magnetic resonance spectroscopy (MRS) following 12–
14 days of hypoglycaemia. Brain glucose content was signi-
ficantly increased by 48%, which is consistent with an in-
crease in the maximal glucose transport rate, Tmax, by 58%
compared with the sham-treated animals. The localized 13C
NMR measurements of brain glucose were directly validated
by comparison with biochemically determined brain glucose
content after rapid focused microwave fixation (1.4 s at 4 kW).
Both in vivo MRS and biochemical measurements implied that
brain glycogen content was not affected by chronic hypogly-
caemia, consistent with brain glucose being a major factor
controlling brain glycogen content. We conclude that the in-
creased glucose transporter expression in chronic hypogly-
caemia leads to increased brain glucose content at a given
level of glycaemia. Such increased brain glucose concentra-
tions can result in a lowered glycaemic threshold of counter-
regulation observed in chronic hypoglycaemia.
Keywords: chronic hypoglycaemia, glucose content, glucose
transport kinetics, glycogen, localized 13C magnetic reson-
ance sprectroscopy, rat brain.
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The maintenance of an adequate supply of glucose from
blood across the blood–brain barrier (BBB) is important
for generating the energy necessary to support normal
brain function. It is generally accepted that glucose content
is not rate-limiting for metabolism in the brain. When
considering the transport steps, i.e. transport across the
endothelial membranes constituting the BBB and cellular
membranes inside the brain, transport of glucose across the
BBB is considered rate-limiting (Gjedde 1980). Given the
importance of glucose transport for normal brain function,
an understanding of its physiology, mechanism and
alterations are of crucial importance to the comprehension
of the maintenance of normal brain function. For example,
brain glucose transport/concentration has been reported to
be increased in chronic hypoxia (Harik et al. 1994, 1995).
The study of glucose transport has received considerable
attention due to its putative implication in the cerebral
mechanism of sensing plasma glucose levels (McCall
2004).
Glucose sensing is accomplished by specialized neurones
(Routh 2003) and is impaired in diabetes as manifested, for
example, by a progressive inability to appropriately release
counter-regulatory hormones in response to antecedent (and
recurring) hypoglycaemia (Dagogo-Jack et al. 1993; Evans
et al. 2000; McCrimmon et al. 2003; Cryer 2004), which is
considered a limiting factor for glycaemic control in Type I
diabetes (Cryer 1994, 1999).
There are several mechanisms that may account for
impaired glucose sensing in the brain as a result of
hypoglycemia (Cryer 2005), one of which is an increase in
glucose transport at the BBB (McCall et al. 1986), supported
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by changes in brain microvascular GLUT1 protein (Kumagai
et al. 1995; Simpson et al. 1999).
Many elegant studies, including autoradiography
(Gjedde and Diemer 1983), positron emission tomography
(PET) (Herholz et al. 1989; Hasselbalch et al. 1999) and
microdialysis (Borg et al. 1999; McCrimmon et al. 2003),
have studied the mechanism of altered glucose sensing
from the BBB glucose transport perspective, with mixed
results. Over the past 10 years, we have developed in vivo
1H and 13C magnetic resonance spectroscopy (MRS)
approaches to determine localized glucose transport kinet-
ics, at steady state, from the measurement of brain glucose
content in rodents (Choi et al. 2001, 2002) and humans
(Gruetter et al. 1998; Seaquist et al. 2001; Criego et al.
2005). The unique capability of localized 13C MRS to
assess brain carbohydrates permits the measurement of the
metabolism and concentration of glucose and glycogen
simultaneously, in a single subject, under physiological
conditions. For example, we recently reported that brain
glycogen, the single most concentrated storage of glucose
equivalents in the brain, can be used as an emergency
reservoir during acute hypoglycaemia (Choi et al. 2003).
Furthermore, it was shown that supercompensation of brain
glycogen occurred following a single episode of hypogly-
caemia. This higher glycogen content was implicated in
the syndrome of hypoglycaemia unawareness that occurs
following a single episode of hypoglycaemia (Cryer 2001;
Choi et al. 2003; Gruetter 2003; Oz et al. 2003). The
rationale for the present study was that while brain
glycogen is a signiﬁcant source of glucose equivalents in
experimental moderate hypoglycaemia (Choi et al. 2003),
it is unlikely to sustain glucose supply deﬁcits during
chronic hypoglycaemia and thus, is not likely to explain
the alterations in counter-regulation observed in, for
example, insulinoma patients (Davis and Shamoon 1991)
or patients with recurrent hypoglycaemia (Boyle et al.
1994).
We therefore sought to determine the effect of chronic
hypoglycaemia on brain glucose concentrations at different
steady-state plasma glucose levels and, concurrently, to
assess the effect of chronic hypoglycaemia on brain
glycogen concentration. We tested the speciﬁc hypothesis
that the previously reported up-regulation of glucose
transport and transporter expression in chronic hypogly-
caemia is accompanied by increased brain glucose content
in a manner consistent with these alterations in gene
expression. Therefore, the purpose of this study was three-
fold:ﬁrst, to assess brain glucose content over a wide range
of steady-state plasma glucose and to determine steady-
state glucose transport kinetics in chronically hypoglycae-
mic rats using 13C MRS; second, to validate the in vivo
NMR quantiﬁcation of brain glucose using a standard
biochemical assay; third, to determine the effect of chronic
hypoglycaemia on total brain glycogen content.
Experimental procedures
Animal model of chronic hypoglycemia
All studies were performed according to the guidelines for the care
and use of laboratory animals at the University of Minnesota and
approved by the Institutional Animal Care and Use Committee
(IACUC). Hypoglycaemia was induced in 18 male Sprague–Dawley
rats (weight ¼ 182 ± 18 g, mean ± SD) on day 0 by subcutaneous
implantation of insulin pellets (6–8 IU/day; Linshin Canada Inc.,
Ontario, Canada) under light isoﬂurane anaesthesia (Simpson et al.
1999). On subsequent days, animals were considered hypoglycae-
mic as judged from morning plasma glucose values that were below
3 mM, measured in spun-down plasma glucose samples obtained
from tail bleeds (average plasma glucose 2.7 ± 0.2 mM, mean ±
SD). An extra insulin pellet (2 IU/day) was administered to maintain
hypoglycaemia. All glucose measurements were obtained using a
glucose analyser (Analox GM7, Analox Instruments, Lunenburg,
MA, USA). NMR studies were carried out on animals that had been
in a hypoglycaemic condition for 12–14 days. A sham-treated group
(average plasma glucose 10.7 ± 0.8 mM, mean ± SD, n ¼ 13)
received an equal number of blank pellets (Linshin Canada Inc.) that
contained no insulin and were otherwise treated identically. In order
to obtain brain glucose and glycogen contents at low plasma glucose
concentrations without 13C glucose infusion, seven animals from
each group were killed and biochemically analysed without further
NMR studies, as described below.
All animals were on a regular light/dark cycle (06:00/18:00
hours) and had access to standard chow and water ad libitum daily,
except for the sham-treated animals, which were fasted 16–18 h
prior to the NMR and biochemical measurements. All NMR
experiments and non-NMR biochemical measurements were started
during the daylight cycle and were randomly distributed into two
starting times at approximately 10:00 and 14:00 hours.
Animal preparation and handling
On the day of the NMR experiment, animals were anaesthetised
with 2% isoﬂurane in a 2 : 1 mixture of nitrous oxide (N2O) and
oxygen (O2), and ventilated with a pressure-driven ventilator (Kent
Scientiﬁc, Litchﬁeld, CT, USA). Once vascular access was secured,
anaesthesia was switched from isoﬂurane to a-chloralose, admin-
istrated with a 40 mg/kg bolus, followed 30 min later by a
continuous intravenous infusion of approximately 26.7 mg/kg/h.
A bolus of 99% enriched [1-13C]-D-glucose (20% weight/volume
solution; Isotec Inc., Miamisburg, OH, USA and CIL Inc., Andover,
MA, USA) was administered, followed by a variable rate infusion to
achieve target steady-state plasma glucose values. Each animal was
ﬁxed stereotaxically with ear bars in a home-made holder, as
described previously (Choi et al. 1999), and placed in the magnet.
Body temperature was maintained at 37C by warm water
circulation (RTE-101 bath circulator, Thermo NESLAB, Ports-
mouth, NH, USA) based on feedback from a rectal temperature
probe (Cole Palmer, Vernon Hills, IL, USA). Throughout the study,
arterial blood was withdrawn at 25–35 min intervals. Arterial blood
gases, i.e. PaO2, PaCO2 and pH were obtained with a blood gas
analyser (Rapidlab 248, Bayer Corp., Newbury, UK) to maintain
identical physiological conditions in both experimental groups, i.e.
(values for the sham-treated group in parentheses, all values mean ±
SD): rectal temperature 36.9 ± 0.2 (36.9 ± 0.3)C; pH ¼
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7.42 ± 0.03 (7.40 ± 0.04); PaCO2 ¼ 40.8 ± 3.0 (39.7 ± 3.2)
mmHg; and PaO2 ¼ 155 ± 17 (153 ± 27) mmHg). Plasma glucose
levels were determined as described above.
Immediately after the NMR experiment and after withdrawing a
plasma sample, the animal was carefully handled and killed by
focused microwave ﬁxation irradiation of the entire brain (Gerling
Applied Engineering Inc., Modesto, CA, USA) at 4 kW in 1.4 s
(Kong et al. 2002). The brain, without cerebellum, was immediately
excised from the skull and stored in a ) 80C freezer (Thermo
Forma, Marietta, OH, USA), for a maximum of 4 weeks, for further
biochemical assay of glucose and glycogen.
13C MRS methods
All experiments were performed in a 9.4 Tesla, 31 cm bore
horizontal magnet (Magnex Scientiﬁc, Abingdon, UK), interfaced
with an INOVA console (Varian, Palo Alto, CA, USA). A
quadrature 1H radiofrequency (RF) 14 mm diameter coil and a
linear polarized three-turn 11 mm diameter 13C RF coil (Adriany
and Gruetter 1997; Choi et al. 2001) was used for MRI and MRS.
FAST(EST) MAP (Fastaumatic shim technique using echo-planar
signal read-out for mapping along projections) shimming (Choi
et al. 2000; Gruetter and Tkac 2000) was applied to adjust B0 ﬁeld
homogeneity in a nominal approximate 440 lL volume of interest
(Choi et al. 1999). Outer volume suppression was optimized for
three-dimensional localization of the NMR signals to ensure
elimination of signals from non-cerebral tissue (Choi et al. 1999).
In order to obtain 13C detectable brain glucose signals, 99%
[1-13C]-D-glucose (20% weight/volume) was infused intravenously
and plasma glucose enrichment approached 99% 2 h after the start
of infusion (Choi et al. 2001). Thereafter, 13C MRS data collection
began. An example of the protocol is shown in Fig. 1. Brain glucose
concentration was determined in spectra acquired after plasma
glucose had been stable for at least 20 min, and when the 13C
glucose signal varied by less than 10%.
Quantification of brain glucose signals
After each in vivo study, a reference phantom experiment identical to
the in vivo measurement was conducted, for absolute quantiﬁcation
of 13C NMR signals of glucose and glycogen, using the external
reference method (Choi et al. 2001). Brieﬂy, signal intensities
(signal area) were corrected for measured small differences in coil
loading and Nuclear Overhauser Enhancement. The reference
phantom contained 8 mM 99% enriched [1-13C]-D-glucose and
400 mM glucosyl units/L of natural abundance glycogen, whose
concentrations were also enzymatically determined. The C1 signals
of glucose were Lorentzian ﬁtted using built-in spectrometer
software, and the total intensity of both a and b glucose signals
was determined. The brain glucose concentration ([Glc]) was
calculated based on the following equation (Gruetter et al. 1998;
Choi et al. 1999, 2001):
½Glc ¼ I
invivo
Glc  IrefFA  8mM
IrefGlc  IinvivoFA
ð1Þ
where I stands for the intensity of either glucose (Glc) or formic acid
(FA) and 8 is the [1-13C]-D-glucose concentration (mM) in the
phantom. The superscripts ‘invivo’ and ‘ref’ indicate measurements
from in vivo animal brain and reference phantom studies, respect-
ively.
Determination of glucose transport kinetics
The reversible Michaelis–Menten (ReMM) model of steady-state
glucose transport kinetics was used to obtain kinetics parameters
from the relation between plasma glucose and brain glucose, using
Fig. 1 An example of the experimental protocol used for chronically
hypoglycaemic animals. On day 0, three insulin pellets (6 IU/day) were
inserted to induce a hypoglycaemic condition (plasma glucose levels <
3 mM), as described in Experimental procedures. On subsequent
days, the hypoglycaemic condition was monitored with morning tail
bleeds. Once plasma glucose rose above the target hypoglycaemic
level, an extra insulin pellet (2 IU/day) was administrated. In this case,
on day 5, the glucose level was slightly higher, and an extra insulin
pellet was inserted. After the chronically hypoglycaemic episode, the
animal was prepared at hour 0, immediately followed by a hyper-
glycaemic clamp. In this case, the steady-state glycaemic level was
maintained for 5 h. To reach a different steady-state glycaemic level,
the infusion rate was adjusted accordingly.
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the following expression (Gruetter et al. 1998) as in previous studies
(Choi et al. 2001, 2002):
Gbrain ¼ Vd 
ð TmaxCMRglc  1Þ  Gplasma  K t
Tmax
CMRglc
þ 1 ð2Þ
where G represents the glucose concentration in brain (lmol/g) or in
plasma (mM), Vd ¼ 0.77 mL/g is the physical distribution space of
water in the brain, Tmax is the apparent maximum transport rate,
CMRglc is the glucose metabolic rate and Kt is the apparent
Michaelis–Menten constant. Consistent with the ReMM kinetic
model, the relationship between plasma glucose and brain glucose at
steady state is linear over a large range of plasma glucose
concentrations (Gruetter et al. 1998). This has been observed in a
number of studies in our laboratory (Choi et al. 2001, 2002;
Seaquist et al. 2001) and by others (de Graaf et al. 2001). The brain
glucose concentration at moderate hyperglycaemia is mostly
inﬂuenced by the relative maximal glucose transport rate, Tmax/
CMRglc (for a derivation see Appendix). For further analysis,
CMRglc was assumed to be unchanged in chronic hypoglycaemia,
based on several reports (Lucignani et al. 1987; Pelligrino et al.
1990; Segel et al. 2001) and on the fact that the measurement of
brain glucose transport kinetics was performed at euglycaemia or
above. The relative Tmax/CMRglc obtained was thus assumed to
reﬂect mainly changes in Tmax.
The small amount of blood volume in rat brain, 3.4 mL/100 g
(Shockley and LaManna 1988), potentially contributes to the total
brain glucose signal from 13C MRS. When subtracting this potential
contribution of blood glucose to the glucose signal based on the
known plasma glucose level, brain glucose content was reduced by
less than 8.5%, which did not affect the qualitative and quantitative
ﬁndings of this study. Fitting of eqn 2 with ORIGIN 5.0 (OriginLab
Corp., Northampton, MA, USA) was performed assuming a ﬁxed Kt
of 3.3 mM (Gruetter et al. 1998; Choi et al. 2001; Choi et al. 2002),
as a Kt ranging from 1 to 6 mM did not affect the quantitative nature
of the ﬁndings of this study, consistent with Kt having a minor
inﬂuence on brain glucose content (see Appendix).
Brain tissue analysis
Extracted brain tissues were stored at ) 80C for less than 4 weeks.
On the day of the assay, frozen tissues were pulverized under liquid
N2 using a mortar. The well mixed brain powder was separated into
two, approximately 200 mg samples. Following extensive valid-
ation, the ‘direct’ HCl glycogen assay was applied (Cruz and Dienel
2002). Brieﬂy, 500 lL 0.03 M HCl were added to each sample, well
homogenized (25 kHz ultrasonic processor, Cole Parmer, Vernon
Hills, IL, USA) and boiled for 45 min at 80–90C in a water bath.
From each sample, two identical 200 lL aliquots were taken and
treated exactly the same, except that 5 lL of 5 mM sodium acetate
was added to the ‘minus’ sample (to yield tissue glucose
concentration) and 5 lL of amyloglucosidase (Roche Diagnostics
Corp., Indianapolis, IN, USA) solution to the ‘plus’ sample (to yield
total tissue glucosyl concentration). pH was adjusted in each sample
to pH 5 by adding a small amount of either 1.1 M HCl or 3 M
sodium acetate. The samples were incubated in parallel in a
reciprocal water bath shaker (New Brunswick Scientiﬁc Co., Inc.,
Edison, NJ, USA) at 37C for at least 2 h. Glucose levels were
determined at room temperature (24C) as described above, and the
readouts were ensured to be in the linear range of the analyser. The
glucose concentration of the brain extract ([Glc]brainextract, lmol/g
wet weight) were calculated from glucose readouts ([Glc]readout)
using the following equation:
½Glcbrainextract ¼ ½Glcreadout 
Wbrainpowder þWHCl
Wbrainpowder
ð3Þ
where W represents the weight (g) from the different source,
indicated by the respective subscript.
Statistics
All data are shown as mean ± SE. Difference between groups was
detected using the Student’s unpaired two-tailed t-test.
Results
Comparing 13C NMR spectra obtained from two animals one
each of the two respective experimental groups illustrated the
profound effect of chronic hypoglycaemia on the brain
[1-13C] glucose C1 signals, which were approximately 50%
higher than those from sham-treated group (Fig. 2). It was of
interest that the brain glycogen C1 signal was detected
clearly after prolonged [1-13C] glucose infusion in both
cases, with a less clear difference between the groups (Fig. 2,
top). Over the entire range of steady-state plasma glucose
levels measured, the corresponding brain glucose concentra-
tions in chronically hypoglycaemic rat brain (open circles in
Fig. 3) were signiﬁcantly higher (p < 0.0001 determined
from the best ﬁt to the data) than the ones in the sham-treated
group (closed squares in Fig. 3). To avoid large errors caused
by the variation of brain glucose with plasma glucose, brain
glucose concentrations were arranged into ﬁve groups, each
deﬁned to correspond to a plasma glucose range of 5 mM
each, i.e. from 5 to 10 mM, 10 to 15 mM, etc. Within each
plasma glucose range, brain glucose in chronic hypoglycae-
mia was increased signiﬁcantly (p < 0.005), with a concen-
tration increase of 48 ± 7% (mean ± SE) when averaged over
the entire plasma glucose range (Table 1).
The steady-state brain glucose concentrations expressed as
a function of plasma glucose was ﬁtted with eqn 2. This
resulted in a relative maximal transport rate of Tmax/
CMRglc ¼ 4.2 ± 0.2 in the chronically hypoglycaemic group
(dashed line in Fig. 3) and Tmax/CMRglc ¼ 2.6 ± 0.1 in the
sham-treated group (solid line in Fig. 3), which represents a
58 ± 7% increase (p < 0.0001).
To validate the in vivo NMR quantiﬁcation of brain
glucose, brains were extracted using microwave ﬁxation and
assayed for tissue glucose, 16 from the chronic hypoglycae-
mia group and 18 from the sham-treated group. The ensuing
quantiﬁcation of brain glucose content was within 10% of
that by NMR and not signiﬁcantly different in both groups,
evidenced by the overlap with the best ﬁt to the NMR data
(dashed line in Fig. 4a and solid line in Fig. 4b). Note the
excellent agreement of the biochemical brain glucose
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quantiﬁcation with the extrapolated NMR ﬁt to low plasma
glucose levels in the chronic hypoglycaemia group (Fig. 4a).
Concurrent assessment of total tissue glycogen content
after about 8 h of hyperglycaemia resulted in 6.9 ± 0.9 lmol
glucosyl U/g (mean ± SD, n ¼ 9) at 6.1 ± 3.6 lmol/g of
brain glucose in the chronic hypoglycaemia group, and
6.0 ± 0.9 lmol glucosyl units/g (mean ± SD, n ¼ 11) at
5.6 ± 2.5 lmol/g of brain glucose in the sham-treated group
(p > 0.05). This was in overall agreement with the NMR
observation of similar brain glycogen content (Fig. 2). In
addition, total brain glycogen in chronic hypoglycaemia
without glucose infusion was not signiﬁcantly higher
(p > 0.05) than in the sham-treated animals (Table 2).
Discussion
The present study is the ﬁrst to report elevated brain glu-
cose content in chronic hypoglycaemia. From the brain
glucose measurements, the observed 48% increase in brain
glucose content was consistent with an estimated 58%
increase in apparent Tmax. In contrast to the increased brain
Fig. 2 Experimental difference in localized
13C glucose signals. The middle and lower
spectra were acquired when plasma glu-
cose levels were 12.2 mM in chronically
hypoglycaemic, and 11.1 mM in sham-
treated animals, respectively. The location
and size of the volume of interest was the
same. The vertical scale was adjusted for
slight differences in loading factor, which
amounted to less than 10%, and the line
broadened to identical line widths of a-glu-
cose C1. The top trace is the difference
between the middle and bottom traces
shown without rescaling. The arrows indi-
cate the respective chemical shift of the
compound indicated.
Fig. 3 Brain glucose concentrations as a function of plasma glucose
levels in the sham-treated (solid squares) and chronically hypoglyc-
aemic animals (open circles). The best fit of the ReMM model (eqn 2)
to the measurements in the sham-treated group resulted in a relative
maximum transport rate of Tmax/CMRglc ¼ 4.2 ± 0.2 between the
chronically hypoglycaemic group (dashed line), and the sham-treated
group (solid line) Tmax/CMRglc ¼ 2.6 ± 0.1 (p < 0.0001).
Table 1 Comparison of steady-state brain glucose content at certain
plasma glucose ranges between chronic hypoglycaemia and sham-
treated groups
Plasma glucose
range (mM) 5–10 10–15 15–20 20–25 25–30
Chronic
hypoglycaemia
(lmol/g)
3.4 ± 0.9
(65)*
5.3 ± 0.7
(65)*
7.6 ± 1.0
(14)*
10.1 ± 1.9
(6)*
11.2 ± 1.0
(12)*
Sham-treated
(lmol/g)
2.5 ± 0.5
(18)
3.9 ± 0.7
(39)
5.5 ± 0.9
(25)
6.2 ± 1.0
(7)
6.9 ± 0.8
(3)
All data are presented as mean ± SD. The number of measurements
is listed in parentheses. For each specific plasma glucose range, the
difference between the two groups was highly significant (*p < 0.005,
unpaired t-test).
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glucose content, brain glycogen levels were not substantially
affected by chronic hypoglycaemia, directly evidenced by
NMR and validated by biochemical measurements.
The increased brain glucose content in chronic hypogly-
caemia could be visualized directly when comparing spectra
obtained at similar plasma glucose levels from the two
different groups (Fig. 2). The elevation of brain glucose was
even more evident after quantifying brain glucose content
over a larger range of steady-state plasma glucose levels
(Table 1 and Fig. 3).
Quantiﬁcation of brain glucose concentrations by 13C
MRS has been veriﬁed in the past by comparing different
NMR measures with each other (Choi et al. 2001). In the
present study, we directly validated the NMR quantiﬁcation
with a standard biochemical assay of brain glucose, which
showed that the accuracy of the NMR quantiﬁcation was
within 10% of that obtained by biochemical methods in both
experimental groups (Figs 4a and b). Considering experi-
mental inaccuracies of both methods, this was deemed an
excellent agreement.
A comparison between brain glucose content as a function
of plasma glucose concentration in the sham-treated animals,
and a previous study using the same anaesthetic protocol
(Choi et al. 2001), indicated that brain glucose concentra-
tions from both groups were indistinguishable (data not
shown). We therefore conclude that the treatment of the
animal with the pellet implants, including the daily treat-
ments such as tail bleeds under 2% isoﬂurane, was without
noticeable effect on brain glucose content as such.
In the chronic hypoglycaemia group as well as the sham-
treated group, the relationship between plasma and brain
glucose at steady state was linear, within experimental limits,
as in previous studies in the rat (Choi et al. 2001, 2002) and
human brain (Gruetter et al. 1998; de Graaf et al. 2001;
Seaquist et al. 2001). Because a potential contribution from
blood glucose to the NMR signal would be linear with
plasma glucose, the linear nature of the relationship between
blood and brain glucose was not affected by this potential
NMR signal contribution from blood glucose. A change in
blood volume of 1 mL/100 g affects the relative fraction of
blood contribution to the brain glucose signal by less 2%.
Thus, hypothetical blood volume changes are well below the
observed increase in brain glucose content. Furthermore, a
potential relative contribution of glucose in blood to the total
signal was much less in chronic hypoglycaemia, due to the
higher brain glucose content. When subtracting the blood
contribution from the NMR quantiﬁcation, both slopes were
reduced by less than 5% and the change of the relative Tmax
remained about 60%, thus not affecting our conclusion.
Fig. 4 Comparison of the NMR measurements with the biochemical
assay of brain glucose in both chronic hypoglycaemia (a) and sham-
treated animals (b). The dashed line in (a) is identical to the dashed
line in Fig. 3, and indicates the NMR quantification of brain glucose in
chronic hypoglycaemia. The open circles represent the concurrent
biochemical determination of glucose in the chronic hypoglycaemia
group. Conversely, the solid line in (b) is the solid line from Fig. 3, and
the solid squares are the respective biochemical determination of brain
glucose.
Table 2 Results of biochemical assay on total brain glycogen and
brain glucose
Group
Brain glycogen
(lmol glucosyl U/g)
Brain
glucose
(lmol/g)
Plasma
glucose
(mM)
Chronic
hypoglycaemia
3.5 ± 0.6 0.9 ± 1.3 2.9 ± 2.2
Sham-treated 3.7 ± 0.6 2.1 ± 0.6 8.2 ± 2.0*
Both chronically hypoglycaemic (n ¼ 7) and sham-treated (n ¼ 7)
animals were killed shortly after chronic hypoglycaemia or sham-
treated episode with no vascular access preparation, glucose infusion
or NMR studies. Plasma glucose concentrations were determined with
tail bleeds. All values are given as mean ± SD; *p < 0.05 (unpaired
t-test). In this case, despite significant different plasma glucose levels
(p ¼ 0.0004), brain glucose (p ¼ 0.057) and glycogen (p ¼ 0.45)
were not significantly different.
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Recent studies using both PET (Hasselbalch et al. 1999)
and 1H MRS (Seaquist et al. 2001) suggested that bulk brain
glucose uptake is largely an insulin-independent process.
Thus, the higher plasma insulin concentration in chronically
hypoglycaemic animals was unlikely to affect our result or
conclusion per se.
The derived glucose transport kinetics indicated a
substantial Tmax/CMRglc increase in chronic hypoglycaemia
(p < 0.0001) that was conﬁrmed using standard biochemi-
cal measurements (Fig. 4). As shown in the Appendix
(eqn A2), brain glucose content is mostly affected by
changes in Tmax/CMRglc. CMRglc in the chronic hypogly-
caemia group was likely the same as that in the sham-
treated group because all NMR data were obtained (i) at
euglycaemia or above, where the brain glucose concentra-
tion was not rate-limiting for metabolism, i.e. above the
Km of hexokinase (50 lM) (Lucignani et al. 1987; McCall
2004), and (ii) under consistent anaesthetic conditions. The
consistency of the anaesthetic regime was further suppor-
ted by the brain glucose concentrations (when expressed as
a function of plasma glucose) in the sham-treated group,
being similar to those in previous studies from our
laboratory using the same anaesthetic protocol. Therefore,
we conclude that an increase in the apparent maximum
transport rate, Tmax, accounts for most of the brain glucose
content change.
Our study used a protocol identical to that of Simpson
et al. (1999), which enabled a direct comparison of the
increase in brain glucose content with the reported changes
of the BBB glucose transporter protein. Simpson et al.
reported speciﬁc changes in GLUT1 expression at the BBB
but no effect on either the astrocytic 45 kDa GLUT1 or the
neuronal GLUT3. This is not surprising, given that beyond
the BBB, glucose is rather uniformly distributed in the
brain’s aqueous phase (Pfeuffer et al. 2000). A plausible
explanation for the lack of effect on the astrocytic and
neuronal transporters is that in the chronic hypoglycaemia
group, the average ambient brain glucose concentration seen
by the cells beyond the BBB can be expected to be similar to
the euglycaemic glucose concentration in the sham-treated
group. The 58% increase in Tmax observed in the present
study is consistent with the 52% increase of luminal GLUT1
in this model (Simpson et al. 1999), but almost twofold
higher than the 23% increase in glucose transporter protein
(GLUT1) at the BBB of the cortex (Simpson et al. 1999).
These observations further support the notion that for
transport of glucose into the brain, the BBB is likely to be
rate-limiting. More speciﬁcally, our results imply that the
density of GLUT1 transporters at the luminal membrane is
rate-determining for transporting glucose into the brain. It
remains to be determined whether the differential increase in
glucose transporter is due to a redistribution of transporters
between the luminal and ablumenal membrane of the brain
endothelium, or whether it involves the presence of a
cytoplasmic glucose transporter pool that, under normal
conditions, is not physiologically active (Barros et al. 2005).
This would be possible, e.g. by having a sequestration of
GLUT1 at the BBB, similar to that of GLUT4 in the muscle.
This scenario would be consistent with recent reports
suggesting that acute regulation of brain glucose transport
might be possible (Barros et al. 2005). To what extent this
occurs, acutely or chronically, remains to be determined.
Some other studies have also indicated a GLUT3 increase
after only 7 (Duelli et al. 1999) or 8 days (Uehara et al.
1997) of chronic hypoglycaemia exposure. This suggests that
GLUT3 is far more sensitive than GLUT1. However, the
discrepancy would not affect our ﬁnal conclusion that brain
glucose increases mainly as a result of increased GLUT1 at
the BBB.
The observed changes in brain glucose content are clearly
ascribed to a consequence of altered GLUT1 gene expression
and its protein product, which occurs only after long-term
exposure (several days) to hypoglycaemia. However, with
increasing frequency and depth, recurrent hypoglycaemia is
likely to approximate the chronic hypoglycaemia protocol
used here in terms of regulation of glucose transport. In
practice, however, episodes of hypoglycaemia rarely last for
hours, and impaired glucose sensing can also be elicited
following a single episode of hypoglycaemia. Therefore, it is
likely that other mechanisms can interfere with glucose
sensing, such as alterations in the efﬁciency of intracellular
glucose-sensing regulators, e.g. glucokinase and ATP-sensi-
tive K+ channels (Levin et al. 2004). An additional potential
mechanism is brain glycogen, an insulin-sensitive glucose
reservoir, which has been shown to be altered following a
single episode of hypoglycaemia (Gruetter 2003).
Whereas during and following acute hypoglycaemia brain
glycogen concentrations are strongly affected (depletion
followed by supercompensation) (Choi et al. 2003), in the
present study brain glycogen content in the chronic hypo-
glycaemia group was similar to that in the control group
(Table 2). This may be surprising, given the reported effects
of lowered plasma glucose concentrations on brain glcyogen
content (see Gruetter 2003; Brown 2004 and references
therein). However, an identical brain glucose level in the two
groups corresponds to two substantially different plasma
glucose levels (Table 2, Fig. 3). This is evident when
drawing a horizontal line in Fig. 3 and considering its
intercept with the best ﬁts (solid and dashed lines in Fig. 3).
Thus, during chronic hypoglycaemia (12–14 days), the brain
glucose concentration is well above the Km of hexokinase,
providing adequate fuel for glucose phosphorylation despite
the apparent mild hypoglycaemia. Therefore, the fact that
glycogen was not depleted was not surprising. Note that the
slightly higher glycogen signal in the chronic hypoglycaemia
animal in Fig. 2 can be explained by a higher isotopic
enrichment (data not shown). This supports the hypothesis
that brain glucose content may have a major controlling
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effect on brain glycogen content (Gruetter 2003; Brown
2004), as was also recently reported for human liver
phosphorylase (Ercan-Fang et al. 2002). As it is likely that
the signal directly stimulating the altered expression of the
glucose transporter is the ambient glucose concentration
itself, the similarity of glucose content beyond the BBB in
both experimental groups can explain the lack of effect of
chronic hypoglycaemia on the astrocytic glucose transporter
(the 45 kDa GLUT1) and the neuronal glucose transporter
protein (GLUT3) (Simpson et al. 1999).
We conclude that chronic hypoglycaemia (12–14 days)
has less effect on brain glycogen content than acute
hypoglycaemia but increases the brain glucose concentration,
most likely due to changes in BBB GLUT1 protein.
Furthermore, such altered glucose transport and transporter
activity could mimic a normal glucose environment in the
brain under the mild hypoglycaemic conditions observed in
the present study (Figs 2 and 3, Table 2). If such an up-
regulation also occurs in proximity to glucose-sensing
neurones, this might contribute to diminished counter-
regulation. These observations reinforce the notion that the
brain is a glucose-sensing organ. An increased brain glucose
content at a given plasma glucose concentration in chronic
hypoglycaemia may thus contribute to impaired glucose
sensing in chronic hypoglycaemia.
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Appendix
In this section, it is shown that the brain glucose concentration is a
sensitive measure of the apparent maximal transport rate relative to
the glucose metabolic rate, v ¼ Tmax/CMRglc.
The change in brain glucose content with respect to changes in
the apparent Michaelis–Menten constant, Kt, and v can be derived
according to ﬁrst-order error propagation theory, using ﬁrst-order
Taylor series expansion of eqn 2, by taking the ﬁrst derivative and
multiplying with the deviation in the respective parameter, i.e. the
change in brain glucose concentration as a function of relative
changes in v and Kt is given by
dGbrain ¼ 0:77
 
vð2Gplasma þ K tÞ
ðvþ 1Þ2
dv
v
Kt
vþ 1
dKt
Kt
!
(A1)
By dividing this expression of eqn 2, and assuming a plasma
glucose of about 16 mM a Kt of about 3 mM (Choi et al. 2001) and v
about 3 eqn A1 simpliﬁes to a relative change in brain glucose
content (Gbrain  5 lmol/g)
dGbrain
Gbrain
 dv
v
 0:1 dK t
K t
(A2)
From this estimation it is clear that under the conditions of the
current study, relative brain glucose concentration changes are 10-
fold more sensitive to relative changes in Tmax than to relative
changes in Kt.
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